Stabilitech appoints new Development Director

Dr Stephen Ward has joined Stabilitech as Development Director, a newly created position as the company expands and enters its next phase. Stephen was previously Director of Development at Onyvax, a cancer vaccine company, and he brings a wealth of experience on vaccine development as well as cGMP manufacturing expertise.

Stabilitech is a privately held company based in London, with a proprietary technology that stabilises vaccines and other biological products, removing the need for refrigeration.